News Update

Govt orders mandatory declaration of stock position of wheatCPI gets Rs 11 Cr tax notice for using old PAN numberGST - Penalty demand of Rs.3731 crores - A person who would fall within the purview of sub-section (1-A) of s.122 should necessarily be a taxable person who retains the benefits of transactions: HCGovt issues advisory against calls impersonating DoTFATP hand-wrings over slow regulation of crypto by member-countriesGST - Threatening and pressurising petitioner who is merely an employee - Highly unconscionable and disproportionate on the part of the officer: HCECI's C-Vigil app a big hit with votersGST - Same relief was claimed in earlier petition which was withdrawn unconditionally - Fresh petition seeking same relief is barred by the estoppel principle: HCIncome tax hands over Rs 1700 Cr tax demand to Congress PartyGST - Neither SCN nor the order spell out the reasons for retrospective cancellation of registration, hence cannot be sustained: HCStage-2 of Vikram-1 orbital rocket successfully test-firedGST - Non-application of mind - If reply was unsatisfactory, details could have been sought - Record does not reflect that such exercise was done - Matter remitted: HCHouthis claim UK has not capability to intercept their hypersonic missilesGST - Merely because a taxpayer has not filed returns for some period does not mean that registration is required to be cancelled with retrospective date also covering the period when returns were filed and taxpayer was compliant: HCIsraeli forces kill 200 Palestinians at Gaza medical complex & arrest over 1000GST - Petitioner's reply, although terse, is not taken into account while passing assessment orders - Petitioner put on terms, another opportunity provided: HCUnveil One Nation; One Debt Code; One Compliance Rule for Centre & StatesChina moves WTO against US tax subsidies for EVs & renewable energyMore on non-doms - The UK Spring Budget 2024 (See TII Edit)Training Program for Cambodian civil servants commences at MussoorieCBIC revises tariff value of edible oils, gold & silverCBIC directs all Customs offices to remain open on Saturday & SundayI-T- Once the citizen deposits the tax upon coming to know of his liability, it cannot be said that he has deliberately or willfully evaded the depositing of tax and interest in terms of Section 234A can be waived: HCHouthis attack continues in Red Sea; US military shoots down 4 dronesCus - No Cess is payable when Basic Customs Duty is found to be Nil: CESTAT
 
NPPA intervenes - 526 brands of 42 anti-cancer drugs reduce prices up to 90%

By TIOL News Service

NEW DELHI, NOV 07, 2020: National Pharmaceutical Pricing Authority (NPPA) has said that its  price rationalisation initiated February 2019 has had the far reaching impact of its decision leading to huge price reduction in anti cancer  drugs. Invoking extraordinary powers in public interest NPPA had launched a Pilot on Trade Margin Rationalisation for 42 anti cancer drugs as a step towards making the healthcare more affordable for the suffering patients.

NPPA in a statement today as part of Observing the National Cancer  Awareness day on 7th November 2020 has said that the decision received unanimous support from all the stakeholders. Based on the feed-back received from the pharmaceutical companies after implementation of the NPPA notification, it was observed that under this exercise 526 brands of 42 anti cancer drugs showed price reduction up to 90%. Percentage wise reduction in prices of brands is as follows: -

S.No

Slab-percentage reduction in prices

No. of Brands

1

75% and above

63

2

50% to 75%

167

3

25% to 50%

169

4

Up to 25%

127

  TOTAL  526

For example, MRP of drug Erlotinib 150 mg tab under Brand Birlotib was revised from Rs.9999/- to Rs.891.79/-, showing a decrease of 91.08%. Similarly, the MRP of Pemetrexed 500 mg injection sold as Pemestar 500 was revised from Rs.25,400/- to Rs.2509/- which was 90% less than pre-revised price. Of the 124 medicines which used to cost more than Rs.20,000/- pre-regulation, only 62 did so subsequently. 

The Pilot has effected annual saving of Rs. 984 crore to cancer patients. It is also a matter of great satisfaction that the Pilot has received immense support from all the stakeholders including patients support groups.

 All India Drug Action Network (AIDAN) has also appreciated the steps taken by NPPA to curb profiteering in sale of anti-cancer medicines by capping the trade margin in public interest.Today also cancer remains as one of the leading causes of adult illness and death due to chronic and non-communicable diseases (NCD) world-over including in India. 

According to World Health Organisation  (WHO), says NPPA, cancer is the second leading cause of death globally and in 2018 there were approximately 18 million cases globally, of which 1.5 million were in India alone. There were around 0.8 million cancer deaths in India in 2018 against 9.5 million globally. The numbers of new cases are estimated to double in India by 2040.  

The financial burden associated with cancer can force patients and households to acute misery, destitution, and even insolvency. Therefore cancer drugs need to be affordable so that whenever required the treatment can be provided at the earliest in the early stages when the cancer is curable. Availability and affordability of cancer drugs will give impetus to treatment outcomes bringing down the cost of treatment.  

The Central Government supplements the efforts of the State Governments to prevent and control cancer and to provide affordable and accessible care. National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) is being implemented under National Health Mission (NHM) for up-to the district level activities.

 Under the ambit of Ayushman Bharat, Pradhan Mantri Jan ArogyaYojana (PM-JAY) is being implemented to reduce the financial burden for poor and vulnerable groups arising out of catastrophic hospital episodes and to provide access to quality health services. It offers a benefit cover of Rs. 5,00,000 per family per year (on a family floater basis).  

 NPPA regulates the prices of all Drugs as per the Drug Price Control Order (DPCO) 2013. It fixes the Ceiling Price of scheduled formulations as per the list of medicines specified in the National List of Essential Medicines (NLEM) which are included in the First Schedule of Drug Pricing Control Order (DPCO), 2013.

By regulating prices of Scheduled Drugs, NPPA roughly covers only 16-17% of the Pharma sector universe. First Schedule of DPCO, 2013 also includes select drugs used for the treatment of cancer. However, there has been a long standing felt need to further regulate the Non Scheduled segment also where high markups have led to arbitrary pricing practices. 


POST YOUR COMMENTS
   

AR not Afar by SK Rahman

TIOL Tube Latest

Shri Shailendra Kumar, Trustee, TIOL Trust, giving welcome speech at TIOL Awards 2023




Shri M C Joshi, Former Chairman, CBDT




Address by Shri Buggana Rajendranath, Hon'ble Finance Minister of Andhra Pradesh at TIOL Awards 2023